{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:36:19Z","timestamp":1740184579264,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00105-023-05154-1","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T07:10:55Z","timestamp":1685689855000},"page":"527-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle dermatologische Leitlinien in Deutschland\u00a0\u2013 Ausgew\u00e4hlte Empfehlungen aus den Jahren 2021 und 2022","Current dermatology guidelines in Germany\u2014selected recommendations from 2021 and 2022"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-8921","authenticated-orcid":false,"given":"A.","family":"Pennitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Breitbart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M.","family":"Clanner-Engelshofen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-4402","authenticated-orcid":false,"given":"H.","family":"Dickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Eisert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Nenoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Paasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zidane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-2203","authenticated-orcid":false,"given":"A.","family":"Nast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"5154_CR1","unstructured":"Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften (Awmf) \u2013 St\u00e4ndige Kommission Leitlinien (2020) AWMF-Regelwerk \u201eLeitlinien\u201c. In:Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)"},{"key":"5154_CR2","first-page":"2154","volume":"94","author":"RE Bloch","year":"1997","unstructured":"Bloch\u00a0RE, Lauterbach\u00a0K, Oesingmann\u00a0U et\u00a0al (1997) Bekanntmachungen: Beurteilungskriterien f\u00fcr Leitlinien in der medizinischen Versorgung Beschl\u00fcsse der Vorst\u00e4nde von Bundes\u00e4rztekammer und Kassen\u00e4rztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl Int 94:2154\u20132155","journal-title":"Dtsch Arztebl Int"},{"key":"5154_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/ddg.14849_g","volume":"20","author":"BM Clanner-Engelshofen","year":"2022","unstructured":"Clanner-Engelshofen\u00a0BM, Bernhard\u00a0D, Dargatz\u00a0S et al (2022) S2k-Leitlinie: Rosazea. J\u00a0Dtsch Dermatol Ges 20:1147\u20131167","journal-title":"J Dtsch Dermatol Ges"},{"key":"5154_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/ddg.14734_g","volume":"20","author":"H Dickel","year":"2022","unstructured":"Dickel\u00a0H, Bauer\u00a0A, Brehler\u00a0R et al (2022) S1-Leitlinie Kontaktekzem. J\u00a0Dtsch Dermatol Ges 20:711\u2013734","journal-title":"J Dtsch Dermatol Ges"},{"key":"5154_CR5","unstructured":"Hillen U (2021) AWMF-S2k-Leitlinie (013-072). Extrakorporale Photopherese (ECP). https:\/\/register.awmf.org\/assets\/guidelines\/013-072l_S2k_Extrakorporale-Photopherese-ECP_2022-02.pdf. Zugegriffen: 30. Nov. 2022"},{"key":"5154_CR6","first-page":"1530","volume":"20","author":"SC Hofmann","year":"2022","unstructured":"Hofmann\u00a0SC, G\u00fcnther\u00a0C, B\u00f6ckle\u00a0BC et al (2022) S2k-Leitlinie zur Diagnostik und Therapie des Schleimhautpemphigoids. J\u00a0Dtsch Dermatol Ges 20:1530\u20131552","journal-title":"J Dtsch Dermatol Ges"},{"key":"5154_CR7","unstructured":"(2021) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Pr\u00e4vention von Hautkrebs, Langversion 2.1. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/hautkrebs-praevention\/. Zugegriffen: 30. Nov. 2022 (AWMF Registernummer: 032\/052OL)"},{"key":"5154_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz\u00a0U, Kragballe\u00a0K, Reich\u00a0K et\u00a0al (2011) Definition of treatment goals for moderate to severe psoriasis: a\u00a0European consensus. Arch Dermatol Res 303:1\u201310","journal-title":"Arch Dermatol Res"},{"key":"5154_CR9","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et al (2021) Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm \u2013 Teil 1: Therapieziele und Therapieempfehlungen. J\u00a0Dtsch Dermatol Ges 19:934\u2013951","journal-title":"J Dtsch Dermatol Ges"},{"key":"5154_CR10","first-page":"1092","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et al (2021) Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm \u2013 Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidit\u00e4t. J\u00a0Dtsch Dermatol Ges 19:1092\u20131117","journal-title":"J Dtsch Dermatol Ges"},{"key":"5154_CR11","volume-title":"European Dermatology Forum (EDF)","author":"A Nast","year":"2022","unstructured":"Nast\u00a0A, Dressler\u00a0C (2022) European Centre for Guidelines Development (EuroGuiDerm). In: European Dermatology Forum (EDF)"},{"key":"5154_CR12","first-page":"1531","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast\u00a0A, H\u00e4fner\u00a0HM, Kolk\u00a0A et al (2021) S3-Leitlinie: Umgang mit Antikoagulanzien und Thrombozytenaggregationshemmern bei Operationen an der Haut. J\u00a0Dtsch Dermatol Ges 19:1531\u20131547","journal-title":"J Dtsch Dermatol Ges"},{"key":"5154_CR13","unstructured":"Nenoff P, Reinel D, Mayser P et al (2022) S1-Leitlinie Onychomykose (AWMF-Register-Nr.\u00a0013-003). https:\/\/register.awmf.org\/assets\/guidelines\/013-003l_S1_Onychomykose_2022-09_1.pdf. Zugegriffen: 30. Nov. 2022"},{"key":"5154_CR14","first-page":"1248","volume":"20","author":"U Paasch","year":"2022","unstructured":"Paasch\u00a0U, Zidane\u00a0M, Baron\u00a0JM et al (2022) S2k-Leitlinie: Lasertherapie der Haut. J\u00a0Dtsch Dermatol Ges 20:1248\u20131270","journal-title":"J Dtsch Dermatol Ges"},{"key":"5154_CR15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/ddg.14830_g","volume":"20","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder\u00a0S, Zeidler\u00a0C, Augustin\u00a0M et\u00a0al (2022) S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus. J\u00a0Dtsch Dermatol Ges 20:1386\u20131402","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05154-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05154-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05154-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:30:00Z","timestamp":1687555800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05154-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5154"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05154-1","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"3 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Hier werden entsprechend den aufgef\u00fchrten Leitlinien die themenrelevanten Interessenkonflikte angegeben. E.\u00a0Breitbart gibt den 1.\u00a0Vorsitz der ADP, 2.\u00a0Vorsitz der NVKH, 1.\u00a0Vorsitz der Hautkrebs-Netzwerk Deutschland e.\u202fV. (HKND), Mitgliedschaft im Fachausschuss Pr\u00e4vention und Fr\u00fcherkennung der Deutschen Krebshilfe (DKH), Mitgliedschaft der Steuerungsgruppe der Allianz f\u00fcr Gesundheitskompetenz und die Mitbegr\u00fcndung des gesetzlichen Hautkrebsscreenings an. H.\u00a0Dickel gibt die Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board) an. L.\u00a0Eisert gibt die Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board) der Unternehmen Novartis Pharma GmbH und eine bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit der Unternehmen PsoNet Berlin und Brandenburg e.\u202fV. und SUN Pharma an. P.\u00a0Nenoff gibt die Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board) mit pers\u00f6nlich erhaltenen Honoraren der Firmen Galderma (Loceryl Nagellack), Almirall Hermal, eine Vortrags- oder Schulungst\u00e4tigkeit mit pers\u00f6nlich erhaltenen Honoraren der Firmen Almirall Hermal, bioM\u00e9rieux, Beiersdorf, Galderma, Janssen, MSD, Dr. Pfleger, Pfizer, Sanofi, Genzyme, UCB Pharma, Autoren- oder Koautorenschaften zu diversen Publikationen zum Thema Onychomykose, ein Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien mit nicht pers\u00f6nlich erhaltenen Honoraren (Mykologie Experten\u00a0\u2013 Labor M\u00f6lbis) des Unternehmens Dr. Pfleger GmbH, Eigent\u00fcmerinteressen durch Aktienbesitz der Firmen Pfizer, Sanofi-Pasteur und die federf\u00fchrende Beteiligung an Fortbildungen\/Ausbildungsinstituten diverser Mykologie-Kurse an. U.\u00a0Paasch gibt eine bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit der Unternehmen Alma Lasers, Tiliaderm UG (haftungsbeschr\u00e4nkt) und Pr\u00e4sidentschaft der DDL an. E.\u00a0Schmidt gibt ein Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien an. S.\u00a0St\u00e4nder gibt eine Berater- bzw. Gutachtert\u00e4tigkeit, Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board) der Unternehmen AbbVie, Almirall, Beiersdorf, Bellus Health, Benevolent, Bionorica, Cara, Clexio, DS Biopharma, Eli Lilly, Galderma, Integrity CE, Kiniksa, Klinge Pharma, Leo Pharma, Pfizer, Sanofi, TouchIMe, Trevi, Vifor, WebMD, eine bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit der Unternehmen Almirall, BMS, Eli Lilly, Sanofi, Galderma, L\u2019Or\u00e9al, Omnicuris, Beiersdorf, Leo Pharma, Novartis, P.\u202fG.\u00a0Unna Academy, Pfizer, UCB, Vifor, bezahlte Autoren-\/oder Koautorenschaften, Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien mit den Organisationen Almirall, German Research Foundation (DFG), European Academy of Dermatology and Venereology (EADV), Leo Pharma, Novartis, Sanofi, Trevi Therapeutics und Interessenkonflikte wegen Dupilumab, Aprepitant und Difelikefalin an. A.\u00a0Pennitz, B.M.\u00a0Clanner-Engelshofen, M.\u00a0Zidane und A.\u00a0Nast geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}